Bulk Anti-Human CD62L (DREG56) Antibody

Human

CD62L

>1mg/ml

Mouse IgG1

Mouse

Anti-CD62L (MEL-14) In Vivo Antibody - Low Endotoxin (ICH1060), Aselizumab Biosimilar - Research Grade (ICH5229)

Aggregation level ≤ 5%

Majority of B cells, naïve T cells, subset of memory T and NK cells, monocytes, granulocytes, thymocytes

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P14151

6402

Blue ice

This is clone DREG56, a mouse monoclonal antibody of the IgG1 isotype (mouse host) raised against human CD62L (L-selectin), one of the most widely used and well-validated anti-human L-selectin clones. As an in-vivo-ready, low-endotoxin research reagent supplied in bulk (milligram to gram scale, RUO), it is suited to functional studies that require large, consistent lots and minimal endotoxin-driven artefacts. Reactivity is human-restricted, so the antibody is primarily applied in human cell systems: flow cytometric identification of L-selectin-expressing leukocyte subsets, Western blot detection of the glycoprotein, and blocking/functional assays that interrogate leukocyte adhesion and rolling. Because the target is human, the antibody is a natural fit for ex-vivo work on primary human PBMCs and lymphocyte subsets, as well as for use in humanized-mouse or human-cell adoptive-transfer settings. The low-endotoxin, bulk format supports reproducible functional and adhesion assays where cell activation must be tightly controlled and where reagent lot-to-lot consistency matters across long study timelines. CD62L (L-selectin, SELL; UniProt P14151) is a type I transmembrane C-type lectin adhesion molecule constitutively expressed on most circulating leukocytes, including naive and central-memory T cells, B cells, monocytes, and neutrophils. Through its lectin domain it binds sialylated, fucosylated, sulfated glycan ligands (such as those presented by GlyCAM-1, CD34, and MAdCAM-1) on high endothelial venules, mediating the initial tethering and rolling that precede firm adhesion and lymphocyte homing to secondary lymphoid organs. L-selectin surface density is dynamically regulated: upon leukocyte activation it is rapidly shed by ADAM17 (TACE)-mediated ectodomain cleavage, so its expression marks less-differentiated, lymph-node-homing subsets and its loss marks effector/effector-memory populations. This makes CD62L a key phenotypic marker for distinguishing naive versus memory T-cell states and a functional node in leukocyte trafficking and inflammation.

L-selectin, SELL, Leukocyte adhesion molecule 1, LAM-11 Leukocyte surface antigen Leu-8, Leukocyte-endothelial cell adhesion molecule 1, LECAM1, Lymph node homing receptor1, TQ12, gp90-MEL, LNHR, LYAM1

DREG56

Anti-CD62L In Vivo Antibody - Low Endotoxin (DREG56) recognizes an epitope on Human CD62L

This monoclonal antibody was purified using Protein A

0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.

anti-CD62L In Vivo Antibody - Low Endotoxin (DREG56) is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Western Blot, Blocking, Functional Assays, Flow Cytometry

Each investigator should determine their own optimal working dilution for specific applications.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Anti-Human CD62L/L-selectin (DREG56) Antibody

Q: Is clone DREG56 suitable for in vivo blocking?

A: Yes, DREG56 is supplied in a low-endotoxin, in vivo-grade format suitable for CD62L blocking and functional studies as well as in vitro work.

Q: Can I order clone DREG56 anti-CD62L in bulk?

A: Yes, it is produced in scalable milligram to gram quantities for bulk and high-throughput experiments.

Q: What does clone DREG56 target?

A: DREG56 is an anti-human CD62L (L-selectin) monoclonal antibody used to study leukocyte adhesion and homing; for research use only.